0001144204-12-066990.txt : 20121207
0001144204-12-066990.hdr.sgml : 20121207
20121207163150
ACCESSION NUMBER: 0001144204-12-066990
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20121109
FILED AS OF DATE: 20121207
DATE AS OF CHANGE: 20121207
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 787 SEVENTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 787 SEVENTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LFB Biotechnologies S.A.S.U.
CENTRAL INDEX KEY: 0001377942
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 121250298
BUSINESS ADDRESS:
STREET 1: 3 AVENUE DES TROPIQUES
STREET 2: LES ULIS
CITY: COURTABOEUF
STATE: I0
ZIP: 91958
BUSINESS PHONE: 33 6 33554531
MAIL ADDRESS:
STREET 1: 3 AVENUE DES TROPIQUES
STREET 2: LES ULIS
CITY: COURTABOEUF
STATE: I0
ZIP: 91958
3
1
v329815_3.xml
OWNERSHIP DOCUMENT
X0206
3
2012-11-09
0
0001001316
TG THERAPEUTICS, INC.
TGTX
0001377942
LFB Biotechnologies S.A.S.U.
3, AVENUE DES TROPIQUES
BP 40305 LES ULIS
COURTABOEUF CEDEX
I0
91942
FRANCE
0
0
1
0
Common Stock
5000000
D
Warrants to purchase Common Stock
0.001
2022-11-09
Common Stock
2500000
D
The warrant becomes exercisable following an equity financing or series of equity financings in which TG Therapeutics, Inc. (the "Company") receives gross proceeds of at least $7,500,000. In addition, the warrant may not be exercised if following the exercise LFB Biotechnologies S.A.S. would beneficially own in excess of 19.9% of the Company's outstanding common stock.
/s/ Brian Keane, Attorney-in-fact
2012-12-07